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1. INTRODUCTION {#mgg31178-sec-0005}
===============

Agnathia‐otocephaly (OMIM 202650) is a rare congenital anomaly pattern with an estimated incidence of less than 1 in 70,000 births. The anomaly is characterized by mandibular hypoplasia, severe micrognathia or agnathia and variable ventromedial auricular malposition and/or fusion and microstomia with microglossia or aglossia. Holoprosencephaly is the most commonly identified associated anomaly, but cyclopia, uni‐/bilateral microphthalmia/anophthalmia, cleft palate, pharyngeal and laryngeal hypoplasia, skeletal, genitourinary, and cardiovascular anomalies, and situs inversus have been reported. The disorder is almost always lethal. It is considered a defect of blastogenesis, resulting in the variable dysmorphogenesis of structures developing from the first pharyngeal arch derivatives or a failure of neural crest cells to migrate into the first and second pharyngeal arches (Faye‐Petersen et al., [2006](#mgg31178-bib-0006){ref-type="ref"}; Opitz, Zanni, Reynolds, & Gilbert‐Barness, [2002](#mgg31178-bib-0014){ref-type="ref"}).

Craniofacial development during embryo‐ and feto‐genesis requires complex interactions of several developmental molecular pathways. Among the pertinent pathways probably involved in the etiology of agnathia‐otocephaly, Sonic Hedgehog (SHH) signaling, bone morphogenetic (BMP) and fibroblast growth factor (FGF) signaling, WNT and glycosylphosphatidylinositol‐anchoring pathways have been suggested (Gekas, Li, & Kamnasaran, [2010](#mgg31178-bib-0007){ref-type="ref"}). However, pathogenic variants in only two genes, *PRRX1* (OMIM 167420) and *OTX2* (OMIM 600037) were reported to be causal for the agnathia‐otocephaly phenotype in a few patients so far, suggesting further genetic heterogeneity. *PRRX1* encodes a homeobox gene, which functions as transcriptional regulator (Kern, Argao, Birkenmeier, Rowe, & Potter, [1994](#mgg31178-bib-0009){ref-type="ref"}), is expressed in undifferentiated human embryonic cranial neural crest cells and most abundantly in cardiac, skeletal, and smooth muscle tissues in adults (Çelik et al., [2012](#mgg31178-bib-0004){ref-type="ref"}). It functions together with other proteins such as PRRX2 and also OTX2, encoded by a homeobox family gene expressed in the developing head, to regulate neural crest cells and the patterning of the first pharyngeal arch as well as skeletal and limb development.

Here we report on non‐consanguineous healthy parents of Albanian descent with a reproductive history of one early miscarriage but an otherwise unremarkable family history. Written informed consent for participation and publication of clinical data and pictures was obtained from the participants. The family was part of a larger study (Meier et al., [2019](#mgg31178-bib-0013){ref-type="ref"}) with approval of the Ethics Commission Northwest Switzerland (EKNZ 2014‐174).

The family came to our attention during the second pregnancy at 19 + 2 weeks of gestation when severe micrognathia was detected by ultrasound and otocephaly suspected (Figure [1](#mgg31178-fig-0001){ref-type="fig"}a,b). Fetal postmortem autopsy revealed an agnathia‐otocephaly complex with severe hypoplasia of the mandible and maxilla, ventral median position of the auricles (Figure [1](#mgg31178-fig-0001){ref-type="fig"}c--d), cheilognathopalatoschisis, microglossia, larynx hypoplasia and esophageal hypoplasia. In addition, the fetus had an aortic isthmus stenosis, fused left lung lobes, a right unilateral rudimental 4th thoracic rib and a cake kidney positioned in the left pelvis with tubular ectasias and megalocytosis of the adrenal cortices. There was no additional brain or eye anomaly. We performed Sanger sequencing for all exons and intron boundaries for both *PRRX1* and *OTX2* but detected no variants.

![(a--e) The affected fetus at 19 + 2 weeks of gestation in prenatal ultrasound (a and b) and post mortem (c--e) showing cheilognathopalatoschisis, microstomia, absent mandible and ventral median positioned auricles. (f) Relative *SMAD3* mRNA expression in kidney and liver tissue of an age‐matched control fetus and the affected fetus (f). RNA was extracted from FFPE tissue, the expression of *SMAD3* was normalized to *GUSB* expression. FFPE, formalin fixed paraffin embedded](MGG3-8-e1178-g001){#mgg31178-fig-0001}

In order to further delineate the etiology of this phenotype we performed family‐based exome sequencing using the trio of fetal DNA extracted from formalin fixed paraffin embedded (FFPE) tissue and parental DNA extracted from blood samples. Library preparation was performed with the Nextera^©^ Rapid Capture Kit for the TruSight One panel (Illumina). Paired‐end read sequencing (2 × 100 bp read length) was accomplished on an MiSeq platform (Illumina). Quality estimation of the sequence reads was performed by generating quality control statistics with FastQC (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc>). The Genome Analysis Toolkit (GATK, <http://www.broadinstitute.org/gatk>) was used to perform variant calling. Variants with a coverage ≤10X and not supported by at least four reads (20%) were discarded. Familial segregation of variants was performed to identify de novo, autosomal recessive and X‐linked recessive inheritance. Hypothesizing a rare Mendelian disorder, we annotated variants as known or novel according to presence or absence in curated databases. Variants were filtered on a heterozygous population frequency (GMAF) of \<5% in control databases (dbSNP150, ExAC, 1000G, gnomAD) and absence of homozygosity in healthy individuals (ExAC, gnomAD). We prioritized variants according to their potential to disrupt protein function including the use of prediction tools (SIFT, Provean, Polyphen2, Mutationtaster, Human Splicing Finder v.3.0), the amino acid conservation (PhyloP, PhastCons) and the American College of Medical Genetics (ACMG) variant classification guidelines (Richards et al., [2015](#mgg31178-bib-0018){ref-type="ref"}). Prioritized variants were inspected for phenotype--genotype correlations reported in humans and other species, based on the medical literature and public databases including functional and expression data (Pubmed, ClinVar, OMIM, HGMD, Uniprot, UniGene, <http://www.zfin.org>; <http://www.informatics.jax.org>; <http://www.mousephenotype.org>). We also focused on genes within the craniofacial developmental pathways including interaction partners of O*TX2* and *PRRX1*.

In the list of de novo variants we prioritized a *SMAD3* (OMIM 603109) missense variant in exon 6 (c.860G\>A, (p.R287Q), LOVD \#0000405920) out of a total of four candidate variants (including variants in *KRT86, PRICKLE1, MYH3*). This variant was previously described as likely pathogenic in a patient with Aneurysms‐osteoarthritis syndrome (AOS) and a patient with Loeys--Dietz‐Syndrome type 3 (LDS3) (Aubart et al., [2014](#mgg31178-bib-0001){ref-type="ref"}; Schepers et al., [2018](#mgg31178-bib-0021){ref-type="ref"}).

Sanger sequencing confirmed the variant in the fetus and its absence in the parents. In silico prediction tools rated the variant as truncating (SIFT, PolyPhen2, Mutationtaster), the HOPE protein prediction (<http://www.cmbi.ru.nl/hope/>) predicted a loss of hydrogen bonds and salt bridges in the protein, due to the amino acid exchange. According to the ACMG guidelines (Richards et al., [2015](#mgg31178-bib-0018){ref-type="ref"}) the variant was classified as likely pathogenic (PM1, PM2, PP3, PP5). SMAD3 is a direct mediator of transcriptional activation by the TGF‐beta receptor. *SMAD3* consists of nine exons that code for an MH1 and MH2 domain, to interact with other SMAD proteins and signal transducing receptors, that are connected through a linker. The variant is located in the MH2 domain of the protein that is highly conserved across species.

To confirm the functional consequence of the variant, mRNA was extracted following the protocol of the RecoverAll^™^ Kit (Ambion) from fetal FFPE liver and kidney tissue of the affected fetus and an age‐matched control fetus without structural anomalies. Kidney and liver were chosen based on tissue availability and the expression data in the Unigene database. Reverse transcription was performed with the High‐Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). SYBR^™^ Green PCR Master Mix (Applied Biosystems) was used for qPCR. Expression levels were normalized to *GUSB* expression. The results showed a significant decrease of *SMAD3* mRNA (Figure [1](#mgg31178-fig-0001){ref-type="fig"}f) up to 44% in kidney and 20% in liver tissue, confirming that the *SMAD3* variant affects the expression of mRNA.

The variant c.860G\>A (p.R287Q), we detected in *SMAD3* in the fetus presenting with agnathia‐otocephaly, was previously reported to cause LDS3 (Aubart et al., [2014](#mgg31178-bib-0001){ref-type="ref"}; Schepers et al., [2018](#mgg31178-bib-0021){ref-type="ref"}), an autosomal dominant connective tissue disorder initially described as AOS (van de Laar et al., [2011](#mgg31178-bib-0022){ref-type="ref"}). These patients present with generalized arterial tortuosity, arterial aneurysms and an increased risk for dissections, in particular for the ascending aorta, craniofacial anomalies including hypertelorism, micro‐/retro‐gnathia, bifid uvula and cleft palate, skeletal and cutaneous anomalies, and early‐onset osteoarthritis (van de Laar et al., [2012](#mgg31178-bib-0023){ref-type="ref"}).

Because of the many overlapping clinical features of LDS type 1 and 2 patients, including the craniofacial anomalies, arterial tortuosity and widespread aneurysms, and harboring autosomal dominant variants in the disease‐responsible genes *TGFBR1/2* and *TGFB2/3* in the same TGF‐β signaling pathway, AOS is now usually classified as LDS type 3 (MacCarrick et al., [2014](#mgg31178-bib-0011){ref-type="ref"}). Schepers and colleagues extensively reviewed known and novel variants in TGFB2/3 ad SMAD2/3 causing a broad phenotypical LDS spectrum (Schepers et al., [2018](#mgg31178-bib-0021){ref-type="ref"}). We suggest, to extend the phenotypic spectrum to agnathia‐otocephaly which may represent the lethal or severe end of the TGFBR/SMAD‐pathway associated phenotypes.

The SMAD family member three gene (*SMAD3*; OMIM 603109) encodes the SMAD3 protein which belongs to the receptor‐activated (R)‐SMAD family. These proteins are intracellular effectors of the canonical transforming growth factor‐β (TGF‐β) signaling pathway including bone morphogenetic proteins (BMPs) that belong to the TGF‐β superfamily (Hata & Chen, [2016](#mgg31178-bib-0008){ref-type="ref"}; Massagué, [2012](#mgg31178-bib-0012){ref-type="ref"}). The SMAD3 protein responds to TGF‐β and regulates TGF‐β‐mediated chondrocyte and osteoblast differentiation (Wu, Chen, & Li, [2016](#mgg31178-bib-0025){ref-type="ref"}). Several studies have shown that SMAD3 deficiency leads also to enhanced BMP signaling and accelerated chondrocyte differentiation which causes osteoarthritis (Li et al., [2006](#mgg31178-bib-0010){ref-type="ref"}).

Furthermore, the SMAD3 protein acts in the same developmental pathway as *OTX2* and *PRRX1* as a transcriptional regulator. This pathway is involved in the development of the first pharyngeal arch in the lower jaw (Gekas et al., [2010](#mgg31178-bib-0007){ref-type="ref"}). Knockout mice show the typical signs of an AOS but also micrognathia (Yang, [1999](#mgg31178-bib-0026){ref-type="ref"}). A knockdown of *SMAD3* in zebrafish resulted in a truncated anterior head and neuronal maldevelopment. However, absence of the lower jaw was not specifically mentioned (Casari et al., [2014](#mgg31178-bib-0003){ref-type="ref"}).

SMAD3 acts in both the TGF‐β and BMP pathway that are crucial for embryonic development. Figure [2](#mgg31178-fig-0002){ref-type="fig"} depicts the complexity of the SMAD3‐related downstream processes. The BMP pathway, where SMAD3 acts as an intracellular effector, is also involved in bone formation (Rahman, Akhtar, Jamil, Banik, & Asaduzzaman, [2015](#mgg31178-bib-0017){ref-type="ref"}). A knockout mouse model of *Alk2*, a BMP receptor, resulted in mice with a hypoplastic mandible, missing jugal bones and enlarged fontanels due to lack of ossification (Dudas, Sridurongrit, Nagy, Okazaki, & Kaartinen, [2004](#mgg31178-bib-0005){ref-type="ref"}). In humans, variants in *BMP4* cause anophthalmia, microphthalmia with brain and digit anomalies (Bakrania et al., [2008](#mgg31178-bib-0002){ref-type="ref"}).

![Roles of SMAD3 in the TGF‐β and the BMP pathway. The SMAD3 protein gets activated through TGF‐β signaling and can act in different downstream pathways. If SMAD3 binds to TRIM33, a chromatin reading and remodeling protein, the complex opens the histone to allow other TFs to enter the DNA. Complexes of SMAD3 and SMAD4 get recruited to different genes, and the transcription of a specific gene is determined by varying partner TFs. In those effector pathways SMAD3 is involved in chondrocyte and osteoblast maturation (Massagué, [2012](#mgg31178-bib-0012){ref-type="ref"}). If SMAD3 binds to DROSHA it regulates the processing of different miRNA precursors. SMAD3 forming a complex with other SMAD proteins driven by BMP signaling also activates transcription via other TFs, regulating various bone formation processes (Rahman et al., [2015](#mgg31178-bib-0017){ref-type="ref"}). TGF‐β, transforming growth factor‐β; TFs, transcription factors](MGG3-8-e1178-g002){#mgg31178-fig-0002}

Interestingly, a loss of function variant in *SMAD3* was recently described as a possible candidate for a patient with holoprosencephaly (Roessler et al., [2018](#mgg31178-bib-0020){ref-type="ref"}). This study concluded that most genes in which variants cause a holoprosencephaly phenotype act in the TGF‐β, hedgehog and FGF signaling pathways. This further supports our hypothesis of agnathia‐otocephaly being a *SMAD3*‐related phenotype, as agnathia‐otocephaly and holoprosencephaly can occur as a combined phenotype (Faye‐Petersen et al., [2006](#mgg31178-bib-0006){ref-type="ref"}; Ozden, Fiçicioğlu, Kara, Oral, & Bilgiç, [2000](#mgg31178-bib-0015){ref-type="ref"}; Puvabanditsin et al., [2006](#mgg31178-bib-0016){ref-type="ref"}; Rodriguez et al., [2019](#mgg31178-bib-0019){ref-type="ref"}; Wai & Chandran, [2017](#mgg31178-bib-0024){ref-type="ref"}).

Agnathia‐otocephaly with or without associated anomalies is clinically and genetically heterogeneous and likely represents the lethal or severe end of a phenotypic spectrum related to variants in genes in the interacting SMAD/TGFB/BMP/SHH/FGF developmental pathways. In order to understand the disease mechanisms and the phenotypic variability, it will be necessary to further study genotype--phenotype correlations as well as the function of genes and their variants in these pathways.
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